Abstract
Wilms tumor is the most common renal malignancy that occurs in children. TP53 gene is considered as a tumor-suppressing gene through controlling cell growth. TP53 gene rs1042522 C>G (Arg72Pro) polymorphism is widely investigated in various types of cancers. However, it is not established if TP53 rs1042522 C>G polymorphism is a candidate variant for Wilms tumor risk. The aim of the study was to determine whether TP53 rs1042522 C>G polymorphism is responsible for the risk of Wilms tumor in Chinese children. All subjects (355 cases and 1070 controls) from four centers of China were genotyped for rs1042522 C>G polymorphism. The effect of rs1042522 C>G polymorphism on Wilms tumor prevalence was analyzed using logistic regression models. We failed to detect a significant relationship between rs1042522 C>G polymorphism and Wilms tumor risk. Further stratification analysis also could not detect a significant relationship. We conclude that TP53 rs1042522 C>G polymorphism might not have enough impact on the risk of Wilms tumor. More validation study with larger sample size will be required to better define the role of TP53 rs1042522 C>G polymorphism in Wilms tumor risk.
Highlights
Wilms tumor is a most frequently occurring renal malignancy in children, with a prevalence of nearly 1 in 10,000 in Western countries [1,2,3]
In classified clinical stages of the cases, 33.52% were diagnosed as clinical stages I, 25.92% were as II, 22.25% were as III, 13.24% were as IV, and 5.07% were as not available (NA)
In order to validate the role of tumor protein 53 (TP53) rs1042522 C>G polymorphism on Wilms tumor risk, we conducted a four-center case–control study with 355 cases and 1070 controls in Chinese population
Summary
Wilms tumor (nephroblastoma) is a most frequently occurring renal malignancy in children, with a prevalence of nearly 1 in 10,000 in Western countries [1,2,3]. In China, the incidence rate of Wilms tumor is approximately 3.3 in one million children between 2002 and 2010 [4]. Wilms tumor typically develops within precursor lesions known as intralobar nephrogenic rests (ILNRs) and perilobar nephrogenic rests (PLNRs) [6]. Nearly 25% of Wilms tumor patients relapse [10,11]. Disappointing events such as 25% of survivors with severe chronic health conditions and high treatment cost await to be solved
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
